摘要：运用相似原理 ,设计出N30 0MW机组低压缸和凝汽器的机械特性模拟实验台。该试验台用于模拟温度、真空、振动、工况等多种因素对低压缸与凝汽器工作的影响 ,从而找到低压缸在多种外界因素的综合作用下产生横向偏移的机理及偏移规律。

摘要：为了高精度地检测长焦透镜的透射波前,提出了在Zygo干涉仪的平面光路中加入一个二元衍射元件提供参考波前的计算全息法(CGH)。介绍了计算全息法检测长焦透镜透射波前的理论,设计并研制了高精度计算全息板,并将其用于大口径长焦距透镜透射波前检测。理论分析和实际检测结果表明:该方法系统误差小,测量重复性精度优于0.004λ(2σRMS),与常规的菲索干涉法测量球面透镜透射波前得到的结果一致,从而验证了提出测量方法的可靠性。最后,详细分析了二元衍射元件的制造误差对透射波前检测的影响,得到测量误差(PV)小于λ/10。文中的结果表明提出的计算全息法可有效缩短光路,提高测量精度,对长焦透镜波前检测有重要的应用价值。

摘要：The traditional zinc hydro-metallurgy generates a large amount of zinc ferrite residue rich in valuable metals. The separation of iron is crucial for resource recycling of valuable metals in zinc ferrite residue. A novel selective reduction roasting？leaching process was proposed to separate zinc and iron from zinc leaching residue which contains zinc ferrite. The thermodynamic analysis was employed to determine the predominant range of Fe3O4 and ZnO during reduction roasting process of zinc ferrite. Based on the result of thermodynamic calculation, we found thatV（CO）/V（CO＋CO2） ratio is a key factor determining the phase composition in the reduction roasting product of zinc ferrite. In the range ofV（CO）/V（CO＋CO2） ratio between 2.68% and 36.18%, zinc ferrite is preferentially decomposed into Fe3O4 and ZnO. Based on thermogravimetric （TG） analysis, the optimal conditions for reduction roasting of zinc ferrite are determined as follows： temperature 700？750 °C, volume fraction of CO 6% and V（CO）/V（CO＋CO2） ratio 30%. Based on the above results, zinc leaching residue rich in zinc ferrite was roasted and the roasted product was leached by acid solution. It is found that zinc extraction rate in zinc leaching residue reaches up to 70% and iron extraction rate is only 18.4%. The result indicates that zinc and iron can be effectively separated from zinc leaching residue.

摘要：目的评价单次口服和多次口服阿兹夫定片在中国健康成年及老年受试者中的药代动力学特征及安全性。方法本研究采取开放、平行方案设计。试验分为2个试验组:健康成年受试者组和健康老年受试者组,分别入组12例受试者。入组的受试者首先进行单次给药,空腹口服阿兹夫定片5 mg,经3 d清洗期后进入多次给药阶段,空腹口服阿兹夫定片5 mg·d^(-1),连续给药7 d。结果单次给予阿兹夫定片5 mg后,健康成年受试者C_(max),AUC_(0-∞)分别为(4.76±2.12)ng·mL^(-1),(6.53±2.20)ng·mL^(-1)·h,T_(max),t_(1/2)的中位数分别为0.75,1.87 h;健康老年受试者平均C_(max),AUC_(0-∞)分别为(6.40±3.25)ng·mL^(-1),(9.50±3.70)ng·mL^(-1)·h,T_(max),t_(1/2)的中位数分别为0.63,2.66 h。连续7 d给予阿兹夫定片5 mg后,健康成年受试者C_(max,ss),AUC_(0-∞,ss)分别为(3.26±1.61)ng·mL^(-1),(5.38±2.19)ng·mL^(-1)·h,T_(max,ss),t_(1/2,ss)的中位数分别为0.88,2.13 h;健康老年受试者平均C_(max,ss),AUC_(0-∞,ss)分别为(3.97±2.09)ng·mL^(-1),(6.71±3.26)ng·mL^(-1)·h,T_(max,ss),t_(1/2,ss)的中位数分别为0.75,2.56 h。单次给药后,健康老年人和健康成年人C_(max)、AUC_(0-t)和AUC_(0-∞)的几何均数比值及其90%置信区间分别为128.37%(88.23%~186.76%)、139.93%(105.42%~185.72%)、140.03%(106.33%~184.41%)。连续7 d给予阿兹夫定片5 mg,健康老年人和健康成年人C_(max,ss)、AUC_(0-t,ss)和AUC_(0-∞,ss)的几何均数比值及其90%置信区间分别为118.66%(80.83%~174.20%)、118.41%(83.60%~167.69%),118.95%(84.78%~166.89%)。结论单次及多次口服阿兹夫定片后,健康老年人与健康成年人相比,系统暴露均有所提高。健康老年人服用阿兹夫定片后,其不良事件和药物不良反应发生的种类、严重程度和发生率与健康成年人相比无明显差异,安全性耐受性良好。